ReviewExpert opinion on pharmacotherapy2015
Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Review in Expert opinion on pharmacotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07231120 (A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia), which is not on this map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of SXRN Injection in Patients With Cancer Cachexia
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Ghrelin for the management of cachexia associated with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Pooled it
- Trial
- Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2016Trial
- Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.European journal of clinical pharmacology · 2026Observational
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Systemic Immune-Inflammation Index is Associated with Pressure Injury in Hospitalized Patients with Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Cancer management and research · 2026Article
- Unlocking the Potential of Obestatin: A Novel Peptide Intervention for Skeletal Muscle Regeneration and Prevention of Atrophy.Molecular biotechnology · 2024Review
- Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.Oncology letters · 2024Article
- Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control.Physiology & behavior · 2023Article
- Binding Domain Characterization of Growth Hormone Secretagogue Receptor.Journal of translational internal medicine · 2022Article
- Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren.Nature communications · 2021Article
- Growth hormone secretagogue receptor-1a mediates ghrelin's effects on attenuating tumour-induced loss of muscle strength but not muscle mass.Journal of cachexia, sarcopenia and muscle · 2021Article
- Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.BMJ open respiratory research · 2020Article
- Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors.Frontiers in oncology · 2020Review
- The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers.Journal of clinical medicine · 2019Review
- Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.International journal of molecular sciences · 2018Review
- Medicinal cannabinoids in palliative care.British journal of clinical pharmacology · 2018Review
- Molecular mechanism of sarcopenia and cachexia: recent research advances.Pflugers Archiv : European journal of physiology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionCancer anorexia-cachexia syndrome (CACS) is associated with increased morbidity and mortality. Anamorelin is a novel, orally active ghrelin receptor agonist in clinical development for the treatment of CACS in NSCLC. The aim of this review is to summarize preclinical and clinical studies evaluating anamorelin as a potential promising treatment for CACS in NSCLC. AREAS COVERED: Pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability of anamorelin for the treatment of CACS in NSCLC were reviewed. Anamorelin administration may lead to increases in food intake, body weight and lean body mass, and a stimulatory effect on growth hormone secretion in NSCLC patients. Anamorelin is well tolerated with no dose-limiting toxicities identified to date. EXPERT OPINION: Targeting ghrelin receptors presents the advantage of potentially addressing multiple mechanisms of CACS simultaneously including appetite, muscle protein balance, adipose tissue metabolism, energy expenditure and inflammation. Clinical data suggest that anamorelin is well tolerated and it effectively increases appetite, body weight and lean mass in patients with advanced NSCLC. Long-term safety remains unknown at this time. The potential synergistic effects of anamorelin with nutritional support or exercise as well as its efficacy/safety in other tumor types are also unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.